Zogenix (ZGNX) Prices 8.52M Share Common Offering at $23/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Stock Movers 03/03: (CVET) (INO) (AMBA) Higher; (CLDX) (HIIQ) (JWN) Lower (more...)
March 3, 2020 5:24 PM ESTToday's After-Hours Stock Movers
Cardlytics (NASDAQ: CDLX) 27.8% LOWER; reported Q4 EPS of $0.18, $0.14 better than the analyst estimate of $0.04. Revenue for the quarter came in at $69.3 million versus the consensus estimate of $63.89 million. Cardlytics sees Q1 2020 revenue of $43.5-46.5 million vs $52.77 million expected.
Covetrus (NASDAQ: CVET) 14.4% HIGHER; reported Q4 EPS of ($0.33), $0.45 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $986.26 million. Covetrus sees FY2020 revenue of $4.025-4.125 billion, versus the consensus of... More
Zogenix (ZGNX) Plans Public Offering of Common Stock
March 3, 2020 5:08 PM ESTZogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the... More
Zogenix, Inc. (ZGNX) PT Lowered to $45 at SVB Leerink
March 3, 2020 9:13 AM ESTSVB Leerink analyst Marc Goodman lowered the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $45.00 (from $48.00) while maintaining a Outperform rating.... More
Zogenix, Inc. (ZGNX) PT Lowered to $60 at Stifel
March 3, 2020 4:31 AM ESTStifel analyst Paul Matteis lowered the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $60.00 (from $67.00) while maintaining a Buy rating.... More
Zogenix (ZGNX) Misses Q4 EPS by 20c, Revenues Beat
March 2, 2020 4:02 PM ESTZogenix (NASDAQ: ZGNX) reported Q4 EPS of ($1.26), $0.20 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $1.95 thousand versus the consensus estimate of $440 thousand.
Fourth Quarter 2019 Financial Results
The Company recorded $1.9 million in revenue for the fourth quarter ended December 31, 2019, as a result of its March 2019 collaboration with Nippon Shinyaku Co., Ltd. for FINTEPLA in Dravet syndrome and LGS in Japan. Zogenix recorded no revenue for the corresponding period of 2018.Research and development expenses for the fourth quarter ended December 31, 2019, totaled $35.8 million, up from $23.6 million in the fourth quarter... More